The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.
July 3rd 2024
Here is your guide to the important regulatory decisions made by the FDA in June 2024.
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
The 14th Asia-Pacific Primary Liver Cancer Expert Meeting
July 18 - 20, 2024
Register Now!
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago
View More
2024 International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Charting the Course for Patients With High-Risk Colon Cancer: 3 Months Versus 6 Months
November 19th 2020In 5 years, it is estimated that approximately 20% of patients with stage II disease and 35% with stage III disease will experience disease recurrence. These estimates highlight the need to pursue progress in adjuvant systemic therapy in order to decrease recurrence rates and improve survival.
Adagrasib Shows Early Efficacy in KRAS G12C-Mutant NSCLC and CRC
November 11th 2020Adagrasib, a novel agent aimed at KRAS G12C mutations, has demonstrated early signs of efficacy in patients with advanced non–small cell lung cancer and colorectal cancer whose tumors harbor the alteration, raising hopes for a new therapy against a challenging oncogenic target.
Adagrasib Shows Early Activity in KRAS G12C+ NSCLC, CRC, and Other Solid Tumors
Adagrasib, a potent and selective inhibitor of KRAS G12C, showcased encouraging clinical activity with an acceptable safety profile in patients with KRAS G12C–positive non–small cell lung cancer, colorectal cancer, and other solid tumors.
Patritumab Deruxtecan Poised for Phase 2 Exploration in HER3+ Advanced CRC
The novel HER3-targeted antibody-drug conjugate patritumab deruxtecan is currently being investigated in a phase 2 trial as a potential treatment for patients with advanced or metastatic colorectal cancer who are resistant, refractory, or intolerant to at least 2 previous lines of systemic therapy.
New Predictive Test Gains Momentum With 2 Positive Studies in Localized Colon Cancer
October 26th 2020Immunoscore®, a host immune response classification tool, has demonstrated the ability to significantly affect treatment decision-making for patients with stage II colon cancer, particularly among those with high-risk disease.
IDE196/Crizotinib Combo Under Exploration in GNAQ/11+ Solid Tumors
October 18th 2020An ongoing, collaborative clinical trial has been expanded to evaluate the investigational protein kinase C inhibitor IDE196 in combination with the multikinase inhibitor crizotinib (Xalkori) for patients with GNAQ- or GNA11-mutated solid tumors, including metastatic uveal melanoma , skin melanoma, lung cancer, and colorectal cancer.